Review Article
Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
Table 1
Genomic and proteomic features of basal-like breast cancer (data from TCGA [
7]).
| Pathways and analysis | Aberrations |
| TP53 pathway | TP53 mut (84%); gain of MDM2 (14%) | PIK3CA/PTEN pathway | PIK3CA mut (7%); PTEN mut/loss (35%); INPP4B loss (30%) | RB1 pathway | RB1 mut/loss (20%); cyclin E1 amp (9%); high expression of CDKN2A; low expression of RB1 | Copy number | Most aneuploid; high genomic instability; 1q, 10p gain; 8p, 5q loss; MYC focal gain (40%) | Proteomic analysis by reverse phase protein array | High expression of DNA repair proteins, PTEN and INPP4B loss signature (pAKT) |
|
|